Plasma Levels of Neuron- and Astrocyte-Derived Exosomal Amyloid Beta1-42, Amyloid Beta1-40, and Phosphorylated Tau Levels in Schizophrenia Patients and Non-psychiatric Comparison Subjects: Relationships With Cognitive Functioning and Psychopathology
Authors:
Open Access
- 2 March 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 11
Abstract
Introduction: Cognitive deficits in people with schizophrenia (PWS) are a major predictor of disability and functioning, yet the underlying pathophysiology remains unclear. A possible role of amyloid and tau biomarkers (hallmarks of Alzheimer's disease) is still speculative in schizophrenia. Exosomes or extracellular vesicles, involved with cell-to-cell communication and waste removal, can be used to assay brain-based proteins from peripheral blood. To our knowledge, this is the first study of exosomal amyloid and tau protein levels in PWS.Methods: This cross-sectional study included 60 PWS and 60 age- and sex-comparable non-psychiatric comparison subjects (NCs), age range 26–65 years. Assessments of global cognitive screening, executive functioning, psychopathology, and physical measures were conducted. Exosomes were extracted and precipitated from fasting plasma and identified as neuron-derived exosomes (NDEs) or astrocyte-derived exosomes (ADEs). Human-specific ELISAs were used to assay levels of amyloid-beta 1-42 (Aβ42), amyloid-beta 1-40 (Aβ40), and phosphorylated T181 tau (P-T181-tau). Plasma assays for aging biomarkers (C-reactive protein and F2-isoprostanes) were also performed.Results: ADE-Aβ42 levels were higher in PWS compared to NCs, though the other exosomal markers were similar between the two groups. Higher ADE-P-T181-tau levels were associated with worse executive functioning. Among PWS, higher ADE-P-T181-tau levels were associated with less severe negative symptoms and increased F2-isoprostane levels. Astrocyte-derived Aβ marker levels were sensitive and specific in differentiating between diagnostic groups. Among PWS, Aβ40 levels differed most by exosomal origin.Discussion: Exosomal markers may provide novel insights into brain-based processes (e.g., aging, oxidative stress) from peripheral blood samples.Keywords
Funding Information
- National Institute of Mental Health (K23MH119375, R01MH094151, T32 MH019934)
- Brain and Behavior Research Foundation (NARSAD Young Investigator Ellen E. Lee, MD)
- National Institute on Aging (P30-AG062429, R01AG051848, R01AG058252)
- Veterans Affairs San Diego Healthcare System
- Sam and Rose Stein Institute for Research on Aging
This publication has 60 references indexed in Scilit:
- Differential Expression of Exosomal microRNAs in Prefrontal Cortices of Schizophrenia and Bipolar Disorder PatientsPLOS ONE, 2013
- The Telephone Interview for Cognitive Status (Modified): Relation with a comprehensive neuropsychological assessmentJournal of Clinical and Experimental Neuropsychology, 2012
- Alzheimer disease biomarkers are associated with body mass indexNeurology, 2011
- Alzheimer's CSF markers in older schizophrenia patientsInternational Journal of Geriatric Psychiatry, 2010
- Cognitive Impairment in Schizophrenia and Affective Psychoses: Implications for DSM-V Criteria and BeyondSchizophrenia Bulletin, 2009
- Sustained Remission of Schizophrenia Among Community-Dwelling Older OutpatientsAmerican Journal of Psychiatry, 2004
- Amyloid β Pathology in Alzheimer’s Disease and SchizophreniaAmerican Journal of Psychiatry, 2003
- Polymorphisms in the tau gene in sporadic frontotemporal dementia and other neurodegenerative disordersEuropean Journal of Neurology, 2002
- Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesionsNeurobiology of Aging, 1994
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992